METHOD OF PREDICTING THE DEVELOPMENT OF PULMONARY EMBOLISM DURING THE PREVENTION OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH A NEW CORONAVIRUS INFECTION Russian patent published in 2023 - IPC G01N33/68 A61B5/107 G01N33/573 

FIELD: medicine; vascular surgery.

SUBSTANCE: invention can be used to predict the development of pulmonary embolism during the prevention of venous thromboembolic complications in patients with a new coronavirus infection. Examination is carried out for the presence of deep vein thrombosis (DVT), determination of the degree of obesity. The level of MCP-1 in the blood serum is determined by enzyme immunoassay, taking into account ongoing anticoagulant therapy — the use of unfractionated heparin (UFH). Then the probability of developing pulmonary embolism is calculated by the formula:

Р=1/(1+е-^Z), where Р is the probability of predicting the development of pulmonary embolism, e is the base of the natural logarithm — the Euler number, and

Z=-7.481+0.008*X1+2.757*X2+2.276*X3+0.667*X4, where X₁ is the initial value of MCP-1 in pg/ml; X₂ is a binary variable reflecting the fact that a patient has DVT: 1 — yes, 0 — no; X₃ — a binary variable reflecting the fact of using UFH in a patient: 1 — yes, 0 — no; X₄ — a categorical variable reflecting the presence and degree of obesity in a patient: 0 — no obesity, 1 — 1st degree, 2 — 2nd degree, 3 — 3rd degree. At P more than 0.07388, the development of pulmonary embolism is predicted during the prevention of venous thromboembolic complications in patients with a new coronavirus infection.

EFFECT: method enables effective prediction of the development of pulmonary embolism by determining the specific pro-inflammatory and prothrombotic marker MCP-1, risk factors and options for anticoagulant therapy in the prevention of venous thromboembolic complications in patients with a new coronavirus infection.

1 cl, 1 dwg, 4 ex